Hepatic dearterialization in the treatment of carcinoid syndrome.
Fourteen patients with carcinoid syndrome due to metastatic ileal (10), ileo-coecal (3) or appendiceal (1) carcinoid tumours were treated with hepatic dearterialization procedures: 15 surgical interruptions of arterial connections to the liver and 1 angiographic embolization of hepatic arteries. 11 patients had complained of recurrent attacks of flush, diarrhea and/or dyspnea and 3 patients had already progressed to general debility and cardiac failure caused by tumour products. Hepatic dearterialization abolished the carcinoid syndrome symptoms for 3-60 months (mean 19 months). Urinary 5-HIAA decreased for a mean period of 27 months. After relapsing symptoms 2 patients had redearterialization of the liver with a renewed symptomless period and lowered 5-HIAA excretion. Operative mortality was 19%: the deaths occurred when liver dearterialization was performed for end-stage patients or simultaneously with bowel resection, which should be considered as contraindications. Hepatic dearterialization seems to be temporarily effective in relieving carcinoid syndrome symptoms and in reducing hormonally active tumour mass and serotonin formation.
D000328:Adult; D000368:Aged; D004621:Embolization, Therapeutic; D005260:Female; D006499:Hepatic Artery / Q000601:surgery*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D008099:Liver / Q000098:blood supply; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000209:etiology / Q000628:therapy* / Q000652:urine; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies
D006897:Hydroxyindoleacetic Acid